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ABSTRACT
Therapeutic antibodies are the fastest 
growing class of drugs in the treatment 
of cancer, and autoimmune and inflam-
matory diseases that require the concom-
itant development of assays to monitor 
therapeutic antibody levels. Here, we 
demonstrate that the use of Affimer 
nonantibody binding proteins provides 
an advantage over current antibody-
based detection systems. For four 
therapeutic antibodies, we used phage 
display to isolate highly specific anti-
idiotypic Affimer reagents, which selec-
tively bind to the therapeutic antibody 
idiotype. For each antibody target the 
calibration curves met US Food and 
Drug Administration criteria and the 
dynamic range compared favorably with 
commercially available reagents. Affimer 
proteins therefore represent promising 
anti-idiotypic reagents that are simple to 
select and manufacture, and that offer the 
sensitivity, specificity and consistency 
required for pharmacokinetic assays.
METHOD SUMMARY
Anti-idiotypic Affimer proteins that bind 
therapeutic antibodies are introduced as 
alternative affinity reagents to traditional 
antibodies. A nonbridging ELISA assay 
for pharmacokinetic analysis of these 
biotherapeutics in serum is developed.
LAY ABSTRACT
The fastest growing class of drugs are 
derived from human proteins that are 
modified to target the processes that 
cause the disease. Owing to the presence 
of similarly structured proteins in the blood, 
it is currently extremely difficult to specif-
ically detect the therapy over the levels 
of normal human proteins in patients. 
However, it is vitally important to be able 
to monitor the levels of these therapies in 
the blood in order to ensure patients receive 
appropriate dosages. This paper describes 
the use of artificially derived proteins, called 
Affimers, to detect four commonly used 
therapies. Overall, we demonstrate that 
Affimer reagents provide a valid approach 
for monitoring dosing of these types of 
drugs.
Monoclonal antibody (mAb) drugs have 
been a resounding clinical and 
commercial success, applied across a 
range of therapeutic areas with a partic-
ularly significant impact in the treatment 
of cancer, autoimmune and inflam-
matory diseases [1–4]. High-interaction 
surface area binding gives mAbs greater 
specificity and so lower off-target, toxic 
effects compared with small-molecule 
drugs [3]. By the end of 2017, 68 mAbs 
or biosimilars were in clinical use and 
the market exceeded US$98 billion in 
sales, having grown every year since 
2013 [5]. This trend looks set to continue; 
therapeutic antibodies are the fastest 
growing class of drugs and in 2017 a 
record number of ten were granted their 
first marketing approvals in the USA or 
EU [1,6]. Further acceleration in mAb 
approvals is expected, with a consid-
erable pipeline of over 550 antibodies in 
clinical development and over 50 in late-
stage clinical trials at the end of 
2017 [1,6].
The advance in antibody thera-
peutics requires a parallel development 
of pharmacokinetic (PK) assays that 
can monitor mAb concentration and 
distribution in patients to guide dosage 
during clinical trials and practice [7,8]. In 
PK assays, the natural antigen may not 
be the optimal mAb capture reagent if it 
is expensive, hazardous or not reliably 
available, or when measurements of 
antigen-bound drug are required [7,9,10]. 
As therapeutic antibodies are highly 
humanized and present among up to 
a million-fold excess of human IgG in 
serum, it is particularly challenging to 
generate capture reagents that avoid 
cross-reactivity [10–12]. Anti-idiotypic 
reagents that bind to the unique 
idiotopes of the antibody variable 
regions are required to specifically 
target the therapeutic antibody in PK 
assays [10,13]. Specific anti-idiotypic 
reagents are also required for immuno-
genicity assays [7,14–16], affinity purifi-
cation [17], analytical studies [18] and 
vaccine development [19–21].
Antibodies are important as 
successful anti-idiotypic reagents, 
but their selection and production can 
be complex and certain limitations 
exist [7,10–12,18,22,23]. With tradi-
tional immunization methods it is hard 
to select for specific binding to the 
antibody idiotype, as binding to other 
regions of the humanized mAb target 
molecules results in serum cross-
reactivity [7,23,24]. Extensive screening 
may be required and long development 
times may not match the pace of drug 
development [7,12,25]. mAb technology 
can, however, be used to more easily 
generate anti-idiotypic reagents. 
Antibody production is also dependent 
on animals or mammalian cell culture 
to ensure correct folding, glycosylation 
and cysteine oxidation [23,26]. This 
complex manufacture is expensive and 
some antibodies have lot-to-lot repro-
ducibility issues, meaning extensive 
validation is required to ensure consis-
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tency throughout the drug evaluation 
process [27–29]. mAbs will not have 
significant lot-to-lot variation but there is 
still a desire for complementary or alter-
native reagents to overcome some limita-
tions. Alternatives include anti-idiotypic 
antibody fragments (antigen-binding 
fragments [Fabs]) [7], single-chain variable 
fragments [11,30], camelid nanobodies [31], 
shark variable new antigen receptors [10] 
and llama single-domain antibodies [32], 
and when directed selection and recom-
binant production is implemented reagents 
can often have improved consistency and 
specificity.
Currently, there is a particular interest 
in developing antibody mimetics based on 
nonimmunoglobulin scaffold proteins with 
randomized, selectable binding regions, as 
they can be engineered to have desirable 
properties [23,33–35]. Many scaffolds 
exist [23]; anti-idiotypic DARPins [22] and 
monobodies [18] have been generated, but 
not validated as reagents in PK assays. A 
promising alternative binding protein is the 
Affimer reagent, which is based on a cystatin 
scaffold with two variable, nine amino acid 
loops that allow high-affinity binding to a 
range of target molecules [36,37]. Affimer 
reagents have been used in numerous 
assays from studying protein function to 
diagnostics [37–47] and exhibit key charac-
teristics that make them potentially suitable 
as anti-idiotypic reagents [45]. They can 
be rapidly identified, incorporating the use 
of negative selection [48] to direct binding 
towards the idiotype and reduce cross-
reactivity. Additionally, the small, stable 
scaffold can be reproducibly produced 
at high yield in E. coli, to give a reliable, 
consistent supply [36,37,48]. Here we 
confirm the suitability of Affimer binders 
as anti-idiotypic reagents; Affimer reagents 
against four therapeutic antibodies have 
been generated, characterized and 
validated for use in PK assays. Lot-to-lot 
reproducibility is evaluated and compar-
isons made with anti-idiotypic Fabs to 
assess the advantages of Affimer reagents 
in terms of specificity, detection range and 
flexibility of assay format.
MATERIALS & METHODS
Target QC
The target antibodies were trastuzumab 
(anti-HER2; Roche, Switzerland), rituximab 
CDR (complementary-determining regions) 
mAb (anti-CD20-hIgG4-mab14; Invivogen, 
CA, USA), adalimumab CDR mAb (anti-TNFα-
hIgG1-mab1; Invivogen) and Ipilimumab 
CDR mAb (Anti-CTLA4-hIgG1-mab1; 
Invivogen). Each target antibody concen-
tration was checked by measuring A280 and 
dividing by the extinction coefficient. A 1-μg 
aliquot of each was analyzed by SDS-PAGE 
(Bolt 4–12% Bis-Tris; Life Technologies, CA, 
USA) to determine quality and purity. A 
100-μg aliquot of each target mAb was then 
biotinylated by incubating in a 10× excess 
of EZ-Link Sulfo-NHS-LC-Biotin (21327, 1 mg 
no-weigh format; Thermo Fisher Scientific, 
MA, USA) for 2 h on ice. Free biotin was 
removed by buffer exchange, the concen-
tration measured and a 1-μg aliquot 
analyzed by SDS-PAGE (as above) to check 
purity. Biotinylation was then confirmed by 
western blot analysis; 200 ng of biotinylated 
target mAb was separated by SDS-PAGE 
(as above) and transferred onto nitrocel-
lulose using an iBlot system (Thermo Fisher 
Scientific). The membrane was then 
blocked using 1× TBS (50 mM Tris, 150 mM 
NaCl; both Sigma, MO, USA) + 3% bovine 
serum albumin (BSA; Sigma) pH 7.4 for 1 h 
at room temperature with gentle agitation 
on a roller mixer. It was then washed for 
3 × 5 min using TBS-T (1× TBS + 0.05% 
Tween 20; Sigma) and detected using a 
1:10,000 dilution of streptavidin horseradish 
peroxidase (HRP; Abcam, UK) in 1× 
TBS + 3% BSA pH 7.4 for 1 h at room temper-
ature. The membrane was then washed as 
described previously and protein detected 
using Amersham ECL detection reagent (GE 
Healthcare Life Sciences, IL, USA), analyzed 
by chemiluminescence using a G:Box gel 
doc system (Syngene, India).
Phage display
Phage display was performed as described 
previously [48]. Briefly, targets were 
submitted to three rounds of phage display, 
with deselection against antibodies of 
similar isotype used to remove cross-
specific binders from the phage output. 
For trastuzumab, a therapeutic antibody 
cocktail (rituximuab, Humira, Avastin and 
human IgG1) was used for deselection. For 
rituximab, adalimumab and ipilimumab 
CDR mAbs, deselection was performed 
with anti-CTLA4 hIgG4, anti-CTLA4 hIgG1 
and anti -TNFa hIgG1 antibodies, 
 respectively.
Primary screen
Following phage display, the Affimer coding 
regions resulting from panning rounds 2 
and 3 were subcloned into pEtLECTRA 
vectors: cHA-His6-Cys for trastuzumab and 
cHA-His6 for the other mAbs. Colonies were 
picked (Table 1) and Affimer proteins were 
expressed in 1-ml cultures and purified 
using Ni-NTA resin (Qiagen, Germany). A 
primary screen was performed using the 
iQue Screener (Intellicyte, NM, USA). Bioti-
nylated targets and deselection targets 
were immobilized onto QSH DevScreen iQue 
beads following the manufacturer’s instruc-
tions (Intellicyte). Affimer protein concen-
trations were normalized to 2.5 μg/ml and 
10 μl added to 10-μl prepared beads in a 
384-well plate. Alexa488-conjugated 
anti-HA antibody (BioLegend, CA, USA) was 
used to quantify Affimer reagent binding. 
Clones were sequenced to identify unique 
Table 1. Number of clones in the primary screen.
Target Clones screened by iQue Hits sequenced Unique sequences
Clones selected for 
ELISA tests
Trastuzumab 360 Top 96 21 21
Rituximab CDR mAb 192 192 102 17
Adalimumab CDR mAb 192 192 15 15
Ipilimumab CDR mAb 192 192 113 16
CDR: Complementary-determining region; mAb: Monoclonal antibody.
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sequences (Table 1).
Affimer protein expression
Medium-scale recombinant Affimer protein 
production (50–100 ml) was performed to 
generate 1–2 mg of Affimer material, which 
was purified by Ni-NTA magnetic beads 
(Qiagen). 5 ml LB (made using LB [Lennox] 
EZ mix powder; Sigma) containing 50 μg/ml 
kanamycin sulphate (Sigma) and 1% (w/v) 
glucose (Sigma) was inoculated with a 
sequence-checked glycerol stock for the 
Affimer reagent of interest and grown for 
16 h at 37°C, 220 rpm. 1 ml of starter culture 
was used to inoculate 100 ml Terrific Broth 
(Melford, UK) containing 50 μg/ml 
kanamycin sulphate and cultures were 
grown at 37°C, 220 rpm until an OD600 of 
0.6–0.8 was reached. The temperature was 
then reduced to 25°C, IPTG (Sigma) added 
to a final concentration of 1 mM and cultures 
incubated at 25°C, 220 rpm overnight. Cells 
were harvested by centrifugation (10,000×g, 
10 min, 4°C) and resuspended in Affimer 
purification lysis buffer (pH 8.0) comprising 
50 mM sodium phosphate (Sigma), 500 mM 
sodium chloride (VWR, PA, USA), 30 mM 
imidazole (Sigma), 10% (v/v) SoluLyse 
(Genlantis, SA, USA), 25 U/ml Benzonase 
Nuclease HC (Millipore, MA, USA) and for 
the trastuzumab Affimer reagent 5 mM TCEP 
(Generon, UK) was also added. The resus-
pended cells were sonicated for 5 min (10 s 
on, 10 s off), then the insoluble fraction was 
removed by centrifugation (10,000×g, 30 min, 
4°C) and the supernatant filtered (0.45 μm) 
to remove any remaining insoluble material. 
Cleared lysates were purified with Ni-NTA 
magnetic beads (Qiagen) using an 
automated process (washed in 50 mM 
imidazole, eluted in 400 mM imidazole). 
Purified trastuzumab Affimer reagents were 
buffer exchanged into pH 6.5 CBS (100 mM 
sodium citrate tribasic dehydrate + 150 mM 
sodium chloride; both Sigma) + 5 mM 
TCEP + 0.02% sodium azide (Severn Biotech, 
UK). Other Affimer reagents were buffer 
exchanged into pH 7.4 PBS (100 mM sodium 
phosphate + 150 mM sodium chloride; both 
Sigma) + 0.02% sodium azide. The concen-
tration (A280/extinction coefficient) and 
purity (1 μg aliquot analyzed by SDS-PAGE) 
of all purified Affimers was measured as 
described previously.
ELISA validation
Selected Affimer binders (Table 1) were 
tested by ELISA. Affimer proteins were 
passively adsorbed onto Maxisorp plates at 
200 nM overnight at 4°C. Plates were washed 
with 1× PBS-T (PBS diluted from 10× PBS; 
Gibco + 0.05% Tween 20; Sigma), using 
3 × 300 μl per well on a BioTek (VT, USA) 
405-plate washer. Wells were then blocked 
with 1× casein-blocking buffer (diluted in 
PBS from 10× casein-blocking buffer; Sigma) 
for 2 h at room temperature with gentle 
agitation. Plates were washed as previously 
and incubated with biotinylated target (at 
target dependent dilution) for 1 h at room 
temperature with gentle agitation. Plates 
were washed again and bound target was 
detected using a 1:10,000 dilution of strep-
tavidin poly-HRP (Pierce, WI, USA) for 1 h at 
room temperature with gentle agitation and 
visualized using tetramethylbenzidine (TMB; 
Surmodics, MN, USA). TMB incubation time 
was target dependent, usually 5–10 min, and 
ODs were read at 450 nm and 630 nm 
(reference wavelength).
Affimer binders selected from the 
validation ELISA were then tested in a 
sandwich ELISA. Affimer reagents were 
passively adsorbed onto Maxisorp plates 
at 1 μg/ml overnight at 4°C. Plates were 
washed and blocked as described previ-
ously before incubation with titrated target 
(twofold dilution from 2000 ng/ml) for 1 h 
at room temperature with gentle agitation. 
Plates were washed again and bound target 
was detected with a 1:100,000 dilution of 
HRP-conjugated anti-hIgG antibody (Bethyl, 
TX, USA) for 1 h at room temperature with 
gentle agitation and visualized using TMB 
(Surmodics). TMB incubation time was 
target dependent, usually 5–10 min, and ODs 
were read at 450 nm and 630 nm (reference 
wavelength).
Assay optimization
The sandwich ELISA protocol was used to 
test selected Affimer proteins for specificity, 
lot-to-lot variation and full curve metrics.
A modified sandwich ELISA protocol was 
used for Fabs (anti-Trastuzumab HCA168, 
anti-Rituximab HCA186 and anti-Adali-
mumab HCA202; BioRad, CA, USA). They 
were passively adsorbed onto Maxisorp 
plates at 5 μg/ml overnight at 4°C, washed 
as described previously and blocked with 
5% BSA in PBS-T (the manufacturer recom-
mended blocking). Plates were washed 
again then the titrated target series was 
incubated for 1 h at room temperature 
with gentle agitation before a final wash. 
Bound target was detected with a 1:10,000 
dilution of mouse anti-human IgG (Fc) CH2 
domain antibody (anti-hFc; BioRad) for 1 h 
at room temperature with gentle agitation 
and visualized using QuantaBlu (following 
manufacturer’s protocol; Thermo Fisher 
Scientific).
Flexibility of detection methods was 
tested using the sandwich ELISA protocol 
with the following minor adaptations: the 
two generic antibodies (anti-hIgG; Bethyl at 
1:100,000 and anti-hFc; BioRad at 1:10,000) 
used the protocol as described except that 
visualization was with QuantaBlu. The 
anti-hIgG Affimer reagent (0.5 μg/ml) was 
pre-incubated with a 1:15,000 dilution of 
streptavidin-HRP (Abcam) in blocking buffer 
before addition to test plate for detection (1 h 
at room temperature with gentle agitation) 
and visualization with TMB.
RESULTS & DISCUSSION
Affimer reagent selection
An Affimer phage display library [36] was 
screened against four therapeutic 
antibodies: trastuzumab (Herceptin) and 
mAbs containing the CDR corresponding to 
the parental therapeutics rituximab 
(Rituxan), adalimumab (Humira) and ipili-
mumab (Yervoy). Screening was performed 
in three successive rounds against bioti-
nylated target mAbs. Each target underwent 
SDS-PAGE to assess the molecular weight 
and purity and biotinylation was confirmed 
by western blot analysis. A negative selection 
procedure [48] was used to direct Affimer 
binding towards the antibody idiotype and 
deselect against the antibody isotype. Small 
amounts of isotype-specific antibody were 
premixed with the phage library in the 
second and third panning rounds, to block 
cross-reactive Affimer binders and selec-
tively isolate specific anti-idiotypic Affimer 
reagents. Outputs from the phage panning 
were subcloned, recombinantly produced 
and purified in a small-scale automated 
process. A high-throughput primary screen 
was performed using the bead-based iQue 
screener (Intellicyt), with target and 
deselection targets immobilized onto 
different beads, such that selective Affimer 
Reports
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binders with no cross-reactivity were 
identified. Clones were sequenced and a 
subset found to be unique. Of these, the 
highest affinity binders identified from iQue 
screening were selected for medium-scale 
(50–100 ml) protein production and purifi-
cation, prior to further ELISA validation. The 
number of clones analyzed from the primary 
screen is summarized for each target in 
Table 1.
An ELISA was used to validate the 
Affimer proteins as capture reagents for 
the biotinylated antibody targets. The best-
performing Affimer reagents were then 
tested in a sandwich format, using an Affimer 
capture surface for the nonbiotinylated mAb 
target and HRP-conjugated anti-human IgG 
antibody (anti-hIgG-HRP) as a detection 
reagent. Based upon the results of this 
screen, a lead candidate Affimer reagent for 
each target was chosen for further charac-
terization. The lead Affimer candidate was 
selected to have the greatest target speci-
ficity and a binding strength optimal for the 
required assay range.
Performance characterization of Affimer 
reagents in PK assay
A sandwich ELISA was developed to assess 
the performance of the selected anti-
idiotypic Affimer reagents in quantifying 
therapeutic antibody concentrations. The 
calibration range of the assay is 
1.95–2000 ng/ml, corresponding to a serum 
concentration of 0.0195–20 μg/ml with 
samples diluted 1:10. This exemplifies the 
potential of Affimer binders as critical PK 
assay reagents, with the scope for clinically 
relevant serum concentrations to be 
measured if samples are diluted further and 
curves run in more diluted matrix [49–53]. 
The anti-idiotypic Affimer reagent was used 
as capture reagent for the target mAb, 
detection was with anti-hIgG-HRP and 
visualization with 3,3′, 5,5″-TMB as the HRP 
substrate. In this assay format each Affimer 
reagent detected its target mAb across a 
broad dynamic range (Figure 1). PK assays 
aim to measure the target therapeutic in 
human serum samples, so require minimal 
sample matrix effects; that is, minimal 
variation in assay performance due to the 
serum matrix in which the assay is 
performed. A sample matrix effect was 
observed in the detection of the rituximab 
CDR mAb in 10% human serum (Figure 1B), 
noted as an increase in background absor-
bance relative to measurements in buffer. 
For all other targets, minimal sample matrix 
effects were observed and each Affimer 
reagent displayed comparable detection of 
the target mAb in 10% human serum as 
shown in buffer (Figure 1). This confirms the 
success of the selection protocols in gener-
ating anti-idiotypic Affimer reagents that 
specifically detect clinically relevant mAb 
concentrations within a human sample 
matrix. The robustness of Affimer reagent 
performance in the presence of serum 
overcomes any need for advance sample 
preparation.
Target specificity of the anti-idiotypic 
reagents within patient sample matrices is 
crucial to ensure the efficacy of the assay, 
as the predominance of natural antibodies 
in the matrix may give rise to inaccurate 
measurements if any cross-reactivity exists. 
In the sandwich assay format, each Affimer 
reagent was highly specific in binding its 
therapeutic antibody target, showing no 
cross-reactivity in the presence of high 
concentrations (1 mg/ml) of alternative 
mAbs, which contain highly homologous 
constant domain regions to the other thera-
peutic antibodies and human IgGs (Figure 2). 
This highlights the value of the deselection 
protocols in driving binding towards the 
idiotype and demonstrates the high speci-
ficity of the isolated Affimer reagents.
Affimer PK assay calibration curves 
assessed against regulatory criteria
The performance of the calibration curves 
for each anti-idiotypic Affimer sandwich 
assay was assessed using section III, B, 2 of 
the US FDA criteria for bioanalytical method 
validation [54]. Calibration curves were 
assessed in terms of the accuracy and 
precision of mAb quantification within a 10% 
human serum matrix. Triplicate measure-
ments at each nominal concentration (1.95–
2000 ng/ml as twofold dilutions) of target 
were performed and a four-parameter 
logistic regression was fitted as a calibration 
curve. For each measurement, an interpo-
lated concentration was then back-calcu-
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Figure 1. Sandwich ELISA dose response curves for target therapeutic antibodies with (A) anti-
trastuzumab (B) anti-rituximab CDR mAb, (C) anti-Adalimumab CDR mAb and (D) anti-ipilimumab 
CDR mAb Affimer reagent capture surfaces. Detection of each target therapeutic antibody was 
compared in buffer (gray) and 10% human serum (red). Anti-hIgG-HGF was used as detection 
reagent, with TMB substrate visualization read at 450 nm (minus 630 nm reference). Data points are 
the mean of triplicate measurements and error bars indicate standard deviation from the mean.  
NB: the majority of the error bars are so small as to be occluded by the data point symbol. 
CDR: Complementary-determining region; mAb: Monoclonal antibody.
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lated from this curve. Intra-assay accuracy 
was determined by percentage recovery; the 
mean interpolated concentration as a 
percentage of the nominal concentration. 
Intra-assay precision was determined by the 
coefficient of variation (% CV); the standard 
deviation of the interpolated concentration 
as a percentage of the mean. This was 
repeated in a total of three separate experi-
ments and the local means used to calculate 
inter-assay accuracy (% recovery) and 
precision (% CV). Each of the calibration 
curves for the four anti-idiotypic Affimer 
reagents meet the following FDA perfor-
mance requirements; at least 75% and a 
minimum of six non-zero standards (inside 
the anchor points) have intra-assay and inter-
assay calibration metrics of ≤20% CV and 
80–120% recovery, with ≤25% CV and 
75–125% recovery at the lower and upper 
limits of quantification (LLOQ/ULOQ) 
(Table 2) [54]. The LLOQ and ULOQ are the 
lowest and highest amount of analyte that 
can be quantitatively determined with 
acceptable precision and accuracy, giving 
the quantifiable range for each therapeutic 
mAb.
The quantifiable range of ipilimumab CDR 
mAb is comparable to that of a commer-
cially available ELISA kit (10–1000 ng/
ml) [55]. The other Affimer ELISAs offer a 
wider quantifiable range than commer-
cially available ELISA kits for trastuzumab 
(11–300 ng/ml), rituximab (3–300 ng/ml) 
and adalimumab (30–1000 ng/ml) [56–58]. 
As the anti-idiotypic Affimer-based assay 
calibration curves meet accuracy and 
precision standards over wide detection 
ranges, this reduces the need for dilutions 
and repetitions, allowing for a wider range 
of samples to be analyzed within a single 
assay. Furthermore, this is achieved with 
just a single specific capture reagent and 
universal detection format, rather than 
requiring two separate specific anti-idiotypic 
reagents, as in the case of many PK bridging 
assays [24]. Antibodies are not limited to the 
bridging format but sufficiently high-quality 
reagents are required.
Consistent lot-to-lot reproducibility in 
the performance of Affimer reagents
Once validated for use in PK assays, it is 
important that a reliable and consistent 
supply of the anti-idiotypic reagent is 
available over the course of clinical devel-
opment and usage. Anti-idiotypic antibodies 
can suffer from poor lot-to-lot reproduc-
ibility; therefore, extensive standardization 
may be required between lots to ensure 
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Figure 2. Specificity of therapeutic antibody detection in a sandwich ELISA using (A) anti-trastu-
zumab (B) anti-rituximab CDR mAb (C) anti-adalimumab CDR mAb and (D) anti-ipilimumab CDR 
mAb Affimer reagent capture surfaces. For each capture surface, detection of 1 mg/ml trastu-
zumab, rituximab CDR mAb, adalimumab CDR mAb and ipilimumab CDR mAb was compared in 
a 10% human serum matrix. Anti-hIgG-HRP was used as detection reagent, with TMB substrate 
visualization read at 450 nm (minus 630 nm reference).
CDR: Complementary-determining region; mAb: Monoclonal antibody.
Table 2. Calibration curve accuracy and precision metrics.
    Trastuzumab Rituximab CDR mAb
Adalimumab CDR 
mAb
Ipilimumab CDR 
mAb
Quantifiable range 
(ng/ml)
ULOQ 1000 1000 1000 1000
 LLOQ ca. 8 ca. 2 ca. 4 ca. 15
Inter-assay % CV 2.3–6.2 2.0–19.4† 1.4–7.1 2.7–11.4
 % recovery 98.1–104.5 95.8–104.6 98.4–106.1 94.4–110.9
Intra-assay % CV 2.8–24.9† 0.7–19.5 1.2–17.3† 0.3–12.0
 % recovery 96.2–109.6 84.0–122.3† 95.4–112.7 91.7–122.6†
†Values approaching FDA limits obtained at a limit of quantification.
CDR: Complementary-determining region; LLOQ: Lower limit of quantification; mAb: Monoclonal antibody; ULOQ: Upper limit of quantification.
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assay performance is maintained [12,25]. 
This can lead to delays in the drug devel-
opment process. Affimer reagents should 
offer low lot-to-lot variability due to their 
simple and robust bacterial manufacturing 
process. The reproducibility of the anti-
trastuzumab Affimer binder was assessed 
as an example of lot-to-lot consistency in 
these reagents. Four separate lots were 
manufactured and compared by analyzing 
the consistency of the sandwich ELISA 
calibration curves (Figure 3) in terms of 
accuracy and precision. 
With each Affimer lot, triplicate measure-
ments of 1.95–2000 ng/ml trastuzumab 
(twofold dilution series) were made in 
10% human serum (Figure 3) and concen-
trations then back-calculated from the 
calibration curve. Although the curve for 
lot 1 was slightly higher than the other 
three assessed, the interpolated values 
of each curve (intra-curve), as well as the 
mean of all four curves (inter-curve), met the 
criteria for accuracy and precision, within 
the previously validated quantifiable range 
(7.8–1000 ng/ml) (Table 3). This confirms 
lot-to-lot consistency in assay performance 
and demonstrates the high reproducibility of 
the Affimer reagent. Anti-idiotypic Affimer 
proteins therefore offer the assurance 
of supply required for critical reagents in 
the bioanalysis of potential therapeutics, 
preventing delays due to extensive lot-to-
lot normalization.
Comparison of Affimer- & Fab-based PK 
assay performance
Anti-idiotypic Fabs are alternative reagents 
that can be selected in vitro and produced 
recombinantly [11,59]. The selected anti-
idiotypic Affimer reagents were compared 
with equivalent Fab reagents, as capture 
reagents for trastuzumab, rituximab CDR 
mAbs and adalimumab CDR mAbs, in a 
sandwich ELISA (Figure 4). Affimer proteins 
were coated at 1 μg/ml and Fabs at 5 μg/ml, 
to generate approximately equivalent molar 
concentrations of capture reagent (∼70 nM 
and 96 nM, respectively). An Fc specific 
detection reagent, HRP-conjugated anti-
human IgG (Fc) CH2 domain antibody (anti-
hFc-HRP), was used to prevent 
cross-reactivity with the Fab and the fluoro-
genic substrate QuantaBlu was used for 
visualization. Using this detection reagent, 
each Affimer capture reagent achieved a 
broad dynamic range for target detection 
with no clear sample matrix effects observed 
in 10% human serum (Figure 4A). The Fab 
capture reagents displayed reduced dynamic 
ranges for the detection of each target 
(Figure 4B). Greater sample matrix effects 
were observed in 10% human serum with the 
anti-adalimumab Fab and particularly the 
anti-rituximab Fab, compared with the equiv-
alent Affimer binder (Figure 4B, ii & iii). This 
reduces the dynamic range of the Fab 
reagents still further in this assay format and 
may lead to inaccurate analysis in patient 
samples due to serum cross-reactivity 
issues. 
The anti-idiotypic Affimer reagents 
therefore exhibit increased target speci-
ficity relative to the Fabs. A single capture 
Affimer reagent offers such specificity that 
a humanized therapeutic antibody can be 
detected in a background of human IgGs 
in serum, using a universal anti-human 
FC (anti-hFc) detection antibody. The Fab 
capture surface offers insufficient speci-
ficity for the use of a universal detection 
format; cross-reactivity leads to the capture 
of serum hIgGs and their detection by 
anti-hFc leads to matrix effects. This issue 
is not inherent to antibodies, but a suffi-
ciently high-quality reagent would need to be 
2
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Figure 3. Lot-to-lot reproducibility of the anti-trastuzumab Affimer reagent as a capture surface in 
a sandwich ELISA. For four separate lots of anti-trastuzumab Affimer capture reagent the dose–
response curves of trastuzumab in a 10% human serum matrix are compared. Anti-hIgG-HRP 
was used as detection reagent, with TMB substrate visualization read at 450 nm (minus 630 nm 
reference). Data points are the mean of triplicate measurements and error bars indicate standard 
deviation from the mean.
Table 3. Anti-Trastuzumab Affimer batch accuracy and precision metrics.
Trastuzumab batch comparison
Calibration range (ng/ml) Inter-batch Intra batch
LLOQ ULOQ %CV %Recovery %CV %Recovery
Ca. 8 1000 0.9–13.7 99.0–117.9† 2.2–20.0† 92.8–120.1†
†Values approaching FDA limits obtained at a limit of quantification.
LLOQ: Lower limit of quantification; ULOQ: Upper limit of quantification.
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Figure 4. Comparison of (A) anti-idiotypic 
Affimer reagents and (B) anti-idiotypic Fabs 
as capture reagents for (i) trastuzumab (ii) 
rituximab CDR mAbs and (iii) adalimumab CDR 
mAbs in a sandwich ELISA. Each anti-idiotypic 
Affimer capture reagent was coated at 1 μg/ml 
(70 nM) and each anti-idiotypic Fab coated at 
5 μg/ml (96 nm). Dose–response curves were 
obtained for the target therapeutic antibody in 
buffer (gray) and a 10% human serum matrix 
(red). Anti-hFc-HRP was used as detection 
reagent, with fluorogenic QuantaBlu substrate 
visualization.
CDR: Complementary-determining 
region; Fab: Antigen-binding fragment; 
mAb: Monoclonal antibody.
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generated. Otherwise, in this case a bridging 
assay format, using the anti-idiotypic Fab 
as capture and detection reagent, would be 
necessary to enhance specificity. However, 
bridging assays often require optimization 
of a low-capture reagent coating density, to 
prevent bivalent binding of the therapeutic 
antibody that precludes binding of the anti-
idiotypic detection reagent [12]. The use of 
such low-capture reagent concentrations 
leads to low sensitivities and high suscep-
tibility to inconsistencies [12]. To avoid this, 
two different anti-idiotypic reagents with 
non-overlapping binding sites would need 
to be found, which is very unlikely due to 
steric issues. Hence, the universal detection 
format afforded by the anti-idiotypic Affimer 
capture approach is extremely desirable 
and less optimization should be required 
from assay to assay. Furthermore, the 
enhanced dynamic range offered by the 
Affimer reagents reduces the need for 
multiple dilutions and minimizes repetition 
of measurements.
Universal Affimer detection reagent
Both anti-hIgG-HRP and anti-hFc-HRP 
antibodies have been successfully used as 
detection reagents, alongside anti-idiotypic 
Affimer capture reagents. Further flexibility 
in detection format was demonstrated by 
the use of a universal anti-hIgG Affimer 
detection reagent (Figure 5), giving an 
Affimer-only assay format. The anti-hIgG 
Affimer was biotinylated and pre-incubated 
with streptavidin-HRP prior to detection and 
visualization with TMB. 
For detection of both trastuzumab and 
rituximab CDR mAbs, minimal matrix effects 
were observed in 10% serum (Figure 5) and 
the dynamic ranges were comparable to 
those obtained with anti-hIgG antibodies. 
The intra-assay curve metrics for trastu-
zumab in 10% serum gave a quantifiable 
range of 2–2000 ng/ml, with ≤18.0% CV 
and 93.9–115% recovery. In 10% serum 
rituximab CDR mAb had a quantifiable 
range of 7.8–2000 ng/ml, with ≤17.7% CV and 
95.3–110.7% recovery. This again demon-
strates the excellent specificity of the 
Affimer capture surfaces, allowing a number 
of different universal detection formats to be 
successfully employed, which offers assay 
developers flexibility to suit individual assay 
requirements. The Affimer sandwich assay 
format obviates the need for antibodies and 
each binding reagent is an easily manufac-
tured recombinant protein. Furthermore, the 
detection reagent is universal, so should be 
applicable across assays, simplifying assay 
development and reagent manufacture.
The generation of anti-idiotypic affinity 
reagents against therapeutic mAbs presents 
a particular challenge. In order to specifi-
cally recognize a humanized therapeutic 
antibody within the high background of 
human IgGs present in serum, reagents 
must be highly specific for the mAb idiotype. 
Here we demonstrate Affimer reagents 
to be easily selected and manufactured 
non-immunoglobulin reagents that can 
address this challenge. Anti-idiotypic 
Affimer reagents against trastuzumab and 
CDR mAbs of rituximab, adalimumab and 
ipilimumab therapeutic antibodies have 
been identified and characterized. A simple 
negative selection protocol successfully 
drove binding towards the target idiotype, 
generating highly specific Affimer binders 
that display minimal matrix effects in 10% 
human serum and no cross-reactivity with 
nonspecific mAbs, without any need for 
affinity maturation. Compared with equiv-
alent Fabs, the anti-idiotypic Affimer capture 
surfaces offered such exquisite specificity 
that a flexible universal detection format 
(anti-hIgG antibody, anti-hFc antibody or 
anti-hIgG Affimer) can be used, avoiding 
bridging assays and simplifying assay 
development. A sandwich ELISA using anti-
idiotypic Affimer capture and universal anti-
hIgG-HRP antibody detection was developed 
within a 10% human serum matrix. 
Calibration curves met the FDA criteria 
for accuracy and precision over favorable 
dynamic ranges in comparison to Fabs and 
commercially available kits, confirming the 
applicability of anti-idiotypic Affimers to PK 
assays. The lot-to-lot consistency of the anti-
trastuzumab Affimer was also confirmed, 
giving assurance of supply.
Overall, it is clear that the Affimer 
platform can be reliably used to develop 
anti-idiotypic reagents for immunoassays, 
to measure relevant concentrations of thera-
4
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Figure 5. Sandwich ELISA dose response curves using anti-hIgG Affimer as detection reagent with (A) anti-trastuzumab and (B) anti-rituximab CDR 
mAb Affimer reagent capture surfaces. Therapeutic antibodies were detected in buffer (gray) and a 10% serum matrix (red). Visualization was with TMB 
substrate read at 450 nm (minus 630 nm reference).
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peutic mAbs with suitable accuracy and 
precision metrics for calibration curves. As 
well as being simple to identify and easy to 
produce, the anti-idiotypic Affimer reagents 
offer performance improvements in terms 
of high specificity, low matrix effects, broad 
dynamic ranges, flexible universal detection 
formats and low lot-to-lot variation. The fast 
reagent development time, ease of assay 
development and assurance of supply make 
the highly specific anti-idiotypic Affimers 
promising reagents to meet the demands 
of clinical development timelines and 
prevent delays, particularly in the growing 
biosimilars arena, where speed to market 
is essential. The development of antibody 
therapeutics continues to expand and anti-
idiotypic Affimer reagents offer the potential 
for critical partner PK assays.
FUTURE PERSPECTIVE
Increasing numbers of biologics entering 
drug development and achieving regulatory 
approval, combined with the rising rates of 
patients suffering with chronic diseases, 
ensures that critical reagents for pharmaco-
kinetic studies will remain an essential 
building block within the drug development 
pipeline. Current pharmacokinetic assay 
reagents can be costly to produce and 
require long development times, which 
hinder the drug development process. As 
the technology driving non-immunoglobulin 
alternatives to antibodies expands, bioana-
lysts will continue to explore both antibody 
and non-antibody-based critical reagents 
when establishing PK and therapeutic drug 
monitoring assays. Reagent selection will 
depend upon superior performance, delivery 
speed and simple and cost-effective assay 
design and development. We foresee that 
these critical reagents may also have appli-
cation in both drug monitoring and patient 
selection in the future.
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